- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Steven Pearson: ICER Can Provide More Information When a Drug is Approved With Limited Data
The Institute for Clinical and Economic Review will work with drug manufacturers, patients, and clinical experts to get supplemental information of newly approved drugs, explained Steven Pearson, MD, MSc, president, ICER.
The Institute for Clinical and Economic Review will work with drug manufacturers, patients, and clinical experts to get supplemental information of newly approved drugs, explained Steven Pearson, MD, MSc, president ICER.
Transcript
How do ICER reports help fill in information gaps of newly approved drugs?
Every drug that comes to market as soon as its FDA approved, there will always be remaining uncertainties. We work on the topic for almost 8 months before FDA approval, and during that time we have the ability to work with the manufacturer to get, often, academic and confidence information that can help supplement what’s available publicly. We’re also able to do a deeper dive into some of the results from the pivotal trials, not just to understand what the label will say but where are the grey areas at the margin or where are some of the comparative issues between this treatment and other potential comparators. So, that’s what our reports try to do, and I would also highlight that during those 8 months, we work very closely with the patient community and with clinical experts because we know that their input is really going to help flush out what we can judge by the evidence and how we can think carefully about how to apply it to coverage criteria and other policies.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
